The coronavirus vaccine market is only a few months old, but it is already worth well over $1 billion. And while companies such as Moderna and Pfizer are currently leaders in this space, others are working to throw their hats into the ring. Two of them are Vaxart (NASDAQ: VXRT) and Ocugen (NASDAQ: OCGN) .
Both companies have recently grabbed quite a few headlines, but Ocugen has been the clear winner in terms of stock market performance since the beginning of the year, or for that matter, over the past 12 months. Past performance aside, which of these two biotechs is more likely to outpace the other from here on out?
Image source: Getty Images
For further details see:
Ocugen or Vaxart: Which Will Take Investors Further?